Biochemical recurrence in prostate cancer: The European Association of Urology prostate cancer guidelines panel recommendations
AuthorsVan der Broeck, T
van den Bergh, R
De Santis, M
van der Kwast, T
van der Poel, H
AffiliationDepartment of Urology, University Hospitals Leuven, Leuven, Belgium
MetadataShow full item record
AbstractBiochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. PATIENT SUMMARY: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions.
CitationVan den Broeck T, van den Bergh RCN, Briers E, Cornford P, Cumberbatch M, Tilki D, et al. Biochemical recurrence in prostate cancer: The European Association of Urology prostate cancer guidelines panel recommendations. Eur Urol Focus. 2019.
JournalEuropean Urology Focus
- Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
- Authors: Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, Cumberbatch M, De Santis M, Tilki D, Fanti S, Fossati N, Gillessen S, Grummet JP, Henry AM, Lardas M, Liew M, Rouvière O, Pecanka J, Mason MD, Schoots IG, van Der Kwast TH, van Der Poel HG, Wiegel T, Willemse PM, Yuan Y, Lam TB, Cornford P, Mottet N
- Issue date: 2019 Jun
- Markers and meaning of primary treatment failure.
- Authors: Swindle PW, Kattan MW, Scardino PT
- Issue date: 2003 May
- Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
- Authors: Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I
- Issue date: 2007 Feb
- [Management of prostate cancer biochemical recurrence in the clinical guidelines].
- Authors: Fernández CH, Patiño GE, Merino RD, Chomón GB, Rios DS, Gárate MM, Gil MJ
- Issue date: 2012 Jan-Feb
- Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
- Authors: Hamada R, Nakashima J, Ohori M, Ohno Y, Komori O, Yoshioka K, Tachibana M
- Issue date: 2016 Jun